Promise of epigenetic modulation as a target in atherosclerotic patients

Promise of epigenetic modulation as a target in atherosclerotic patients
10' education - Aug. 26, 2017 - Barcelona, Spain - Erik SG Stroes, MD, Amsterdam, the Netherlands - PACE-CME symposium at ESC 2017 - Online CME
  • Overview

    This lecture was part of a CME accredited symposium: 'Managing Diabetes & CVD: Is epigenetics a new way forward?' held at ESC 2017 in Barcelona on August 26, 2017

  • Educational information

    The educational objectives of this symposium were to:

    • To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
    • To understand the origin of the high residual cardiovascular risk in patients with diabetes, ACS
    • To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD
    • To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management
  • Faculty

    Erik Stroes, MD, is Internist Vascular Medicine, Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands

  • Disclosures

    This symposum was supported by an unrestricted educational grant provided by Resverlogix

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free